Rigel Pharmaceuticals | RIGL - Equity Capital And Reserves


Rigel Pharmaceuticals reported $117.61M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -271.11M 3.03M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Celldex Therapeutics USD 527.16M 71.2M Dec/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Veracyte USD 1.26B 36.61M Sep/2025